This symposium will explore the rapidly evolving landscape of treatment for recurrent low-grade serous ovarian cancer (LGSOC), with a focus on newly FDA-approved therapies and investigational strategies, MEC Inhibitors, CDK46 Inhibitors, hormonal treatments and other opportunities in the competitive landscape. LGSOC remains a challenging subtype due to its unique biology and resistance to conventional therapies. Faculty will examine recent clinical trial data, discuss emerging best practices for biomarker testing and sequencing, and explore practical considerations for managing side effects and ensuring patient access to innovative treatments. Through real-world cases and interactive discussion, participants will gain insights to personalize care and optimize outcomes for patients living with recurrent LGSOC.
What is GOG GYN-LIVE - INDUSTRY SUPPORTED SYMPOSIA?
The GOG Foundation, Inc. and GOG Partners are thrilled to share enduring education from Industry Supported Symposia that showcases clinical trials and other newsworthy education, from major medical meetings throughout the year.